Conditions: Breast Neoplasms
Keywords: HER2/HER3 Bispecific Antibody Breast Cancer Advanced Breast Cancer Metastatic Breast Cancer HER2 Positive Breast Cancer Trastuzumab Herceptin
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 16
Healthy volunteers: no

Brief summary:
This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.

Detailed description:
Phase 1: Safety and tolerability of the MM-111 + Herceptin combination will be evaluated and the recommended Phase 2 dose will be determined.

Arms:
arm 1: MM-111 will be combined with Herceptin

Interventions: intervention 1: MM-111 + Herceptin
Intervention descriptions: intervention 1: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV

Protocol document: